Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine with or without trastuzumab beyond progression in HER2-positive metastatic breast cancer
2005-002084-85Phase 3Completed
- Sponsor
- GBG Forschungs
- Start
- Oct 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Capecitabine alone with Capecitabine + trastuzumab (2 arms). Primary endpoint: Time to disease progression. Started Oct 2005; status: completed.
02
Drugs
capecitabinetrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-002084-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002084-85.